Still doing my homework but I'm thinking they'll get the 5% for 10 years that Progenics agreed upon first PRO 140 commercial sale.
I think there's another 5% that goes to Abbvie also.
Since the turnover of PRO 140 to CytoDyn was so long ago, those costs have been absorbed/written off the books and whatever royalty revenue LNTH/ABBV gets is going to fatten up their quarterly income statements.
I'll do some digging and slide it to you via email.